Take2 Health and Pantai Premier Pathology Joining Hands to Promote Early NPC Detection
Take2 Health (“Take2”) and Pantai Premier Pathology joined hands to offer the Take2 Prophecy™ Test for Nasopharyngeal Cancer (“NPC”) in Malaysia, aiming to identify early-stage NPC patients and thereby enable timely diagnosis and treatments for patients in Malaysia.
Pantai Premier Pathology is a medical laboratory offering a comprehensive range of laboratory services under IHH Healthcare, one of the world’s top 10 healthcare groups by market capitalisation. This collaboration is a significant milestone in early cancer detection in Southeast Asia and also the first step of Take2 to advocate the broader use of innovative biotechnology in Malaysia.
NPC is vastly common among Southeast Asian countries, ranking 5th in terms of cancer incidence, with over 2,000 new cases reported in Malaysia in 2018[1]. Leveraging the cutting-edge Next- generation Sequencing technology, together with the local medical network of Pantai Premier Pathology, Take2 is confident to work with Malaysia’s clinicians to foster better clinical outcomes and patient experience in the battles against cancers.
[1] Ting, S. H., Brahmana, R. K., & Jerome, C. (2021). Factors Influencing Intention to Undertake Nasopharyngeal Cancer Risk Reducing Behaviors. Asia-Pacific Social Science Review, 21(1).
More Latest News
Nasopharyngeal Cancer Screening Results May “Predict” Development of Related Cancer and Improve Early Diagnosis, CUHK Study Finds
A recent study conducted by The Chinese University of Hong Kong (CUHK)’s Faculty of Medicine (CU Medicine) has shown that individuals with detectable plasma Epstein–Barr virus (EBV) DNA but without an immediately identifiable nasopharyngeal cancer (NPC) after further investigation with nasal endoscopic examination and magnetic resonance imaging (MRI), have a higher risk of developing NPC in 3 to 5 years, up to 17 times higher than those tested “negative” in the test. The non-invasive liquid biopsy techniques not only could be used for early cancer detection but may also indicate the risk for future cancer development.
Promoting NPC Awareness across the City
Joining Hands with Bowtie to Sponsor the Take2 Prophecy™ Test for Nasopharyngeal Cancer to the High-risk Group
Awarded as The Company with the Most Investment Potential & The Top Breakthrough Innovation
Take2 Health are privileged to have participated in the first ZAODX World Conference on Early Detection of Cancer, and are very honoured to be awarded as The Company with the Most Investment Potential (金篩獎‧最具投資價值潛力企業) as well as The Top Breakthrough Innovation (金篩獎‧突破性創新獎)
